Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer.

Trial Profile

Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer.

Completed
Phase of Trial: Phase 0

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab; Cisplatin; Erlotinib
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2011 Actual end date 1 Apr 2010 identified as reported by ClinicalTrials.gov.
    • 30 Aug 2011 Trial phase changed from I/II to 0 as reported by ClinicalTrials.gov.
    • 30 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top